Location History:
- Nantes, FR (2018 - 2020)
- Lausane, CH (2022)
- Lausanne, CH (2017 - 2023)
Company Filing History:
6 out of 6 
3 out of 141 
2 out of 2 
Years Active: 2017-2023
Title: The Innovative Contributions of Jean-Marc Le Doussal
Introduction
Jean-Marc Le Doussal is a prominent inventor based in Lausanne, Switzerland. He has made significant contributions to the field of biotechnology, particularly in cancer treatment. With a total of 8 patents, his work focuses on the development of antibodies that enhance the therapeutic potential of drugs.
Latest Patents
Among his latest patents is a method for the delivery of an anti-cancer agent into a cell expressing the O-acetylated GD2 ganglioside. This method utilizes an antibody that specifically recognizes the OAcGD2 ganglioside. Another notable patent involves a humanized antibody against the O-acetylated GD2 ganglioside, which includes a humanized light chain variable region and a humanized heavy chain variable region. This antibody has applications in both diagnostics and therapy.
Career Highlights
Jean-Marc has worked with notable organizations such as Ogd2 Pharma and Université de Nantes. His experience in these institutions has allowed him to collaborate with other experts in the field and further his research in antibody development.
Collaborations
Some of his coworkers include Mylene Dorvillius and Mickael Terme. Their collaborative efforts have contributed to the advancement of innovative solutions in cancer therapy.
Conclusion
Jean-Marc Le Doussal's work exemplifies the impact of innovation in biotechnology. His patents and collaborations highlight his commitment to improving cancer treatment through advanced antibody research.